Condition
Malignant|Pleural|Mesothelioma
Estimated Enrollment: 26
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 2010/VCC/0049|2010-023230-22
Study First Received: March 28, 2012
Last Updated: March 11, 2013
Estimated Primary Completion Date: June 2014
Primary Outcome Measures:
Immune response to 5T4 and MVA antigens as measured by intracellular cytokine staining (ICCS)|Safety and tolerability|Clinical activity in terms of PFS, ORR and OS|Relationship between immune response and clinical response|Identify potential predictors of treatment benefit
Sponsors and Collaborators:
Wales Cancer Trials Unit|Velindre NHS Trust|June Hancock Mesothelioma Research Fund|Velindre Cancer Centre Stepping Stones Appeal
Website Link: https://ClinicalTrials.gov/show/NCT01569919
